Medicure Inc (MCUJF) 1.8500 $MCUJF
Medicure Announces Grant Of Options
PR Newswire - Tue Jul 07, 5:08PM CDT
Medicure Inc. (the "Company"
(TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of 240,000 options to Knight Therapeutics Inc. ("Knight" pursuant to the Company's Stock Option Plan and to the Company's advisory services agreement with Knight as announced April 14, 2014. The options are set to expire on the fifth anniversary of the date of grant and were issued at an exercise price of $2.50 per share. The options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 2.370 (+0.010)
IIROC Trade Resumption - Medicure Inc.
Newsfile Corp - Thu Jun 11, 6:58AM CDT
Trading resumes in:
IIROC Trade Halt - Medicure Inc.
Newsfile Corp - Wed Jun 10, 2:42PM CDT
The following issues have been halted by IIROC:
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.16 (+0.33), BMRN: 141.67 (+1.54), TRGT: 2.68 (-0.06), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch), NVS: 103.22 (+3.20)
Global Tardive Dyskinesia Clinical Trials Report 2015
M2 - Fri May 22, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mndbr/tardive) has announced the addition of the "Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" report to their offering. Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tardive Dyskinesia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Neurocrine Biosciences, Inc. - Teva Pharmaceutical Industries Limited - UCB S.A. - Synchroneuron Inc. - Medicure Inc. Clinical Trial Overview of Top Institutes / Government - Beersheva Mental Health Center - Beijing Huilongguan Hospital - Taoyuan Mental Hospital - Baylor College of Medicine - Ben-Gurion University of the Negev - Centre for Addiction and Mental Health - Centre Hospitalier Universitaire, Amiens - Herzog Hospital - Lawson Health Research Institute - Parnassia Psycho Medical Centre For more information visit http://www.researchandmarkets.com/research/9mndbr/tardive
NBIX: 48.16 (+0.33), TEVA: 61.38 (-0.75)
Medicure Reports Financial Results for the First Quarter of 2015
CNW Group - Wed Apr 29, 6:11PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the first quarter ended March 31, 2015.
MPH.VN: 2.370 (+0.010)
Medicure Q1 Results and Conference Call Dates
PR Newswire - Mon Apr 27, 12:32PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will release financial results for the first quarter after market close on Wednesday April 29, 2015. Medicure will hold a conference call regarding the results on Thursday April 30, 2015 at 8:00 am, Central Time. (9:00 am, Eastern Time).
MPH.VN: 2.370 (+0.010)
Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT®
PR Newswire - Thu Apr 23, 10:14AM CDT
FDA Approves Labeling Supplement
MPH.VN: 2.370 (+0.010)
Medicure to present at the 2015 Bloom Burton & Co. Healthcare Conference
CNW Group - Wed Apr 22, 10:14AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the Company's President and Chief Operating Officer, Dawson Reimer, will present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 5, 2015 at 11:30 a.m. Eastern Time.
MPH.VN: 2.370 (+0.010)
Medicure reports financial results for the seven months ended December 31, 2014
PR Newswire - Tue Apr 14, 10:35AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the seven months ended December 31, 2014.
MPH.VN: 2.370 (+0.010)
Medicure announces grant of options
CNW Group - Fri Mar 27, 2:49PM CDT
Medicure Inc. (the "Company" (TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 236,070 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 181,070 are set to expire on the tenth anniversary of the date of grant, 5,000 are set to expire on the third anniversary of the date of grant and 50,000 are set to expire on the first anniversary of the date of grant. All of the options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 2.370 (+0.010)
Medicure announces issuance of shares under previously announced shares for debt settlement
PR Newswire - Fri Mar 20, 4:00PM CDT
Medicure Inc. (the "Company" (TSXV:MPH, OTC:MCUJF.US) announces today that the Company has issued 108,206 of its common shares at a deemed price of $1.44 per common share extinguishing $155,816.64 of amounts owing to certain members of the Board of Directors and a consultant under shares for debt agreements originally entered into and announced on January 27, 2015. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
MPH.VN: 2.370 (+0.010)
Medicure provides quarterly revenue on a calendar basis following change to year end
PR Newswire - Mon Feb 02, 9:00AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today provided detail on its historic calendar quarter revenue in anticipation of future reporting under the new financial reporting periods. This change in year end from May 31 to December 31 was previously announced on December 18, 2014.
MPH.VN: 2.370 (+0.010)
Medicure Announces Grant Of Options
PR Newswire - Tue Jul 07, 5:08PM CDT
Medicure Inc. (the "Company"
(TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of 240,000 options to Knight Therapeutics Inc. ("Knight" pursuant to the Company's Stock Option Plan and to the Company's advisory services agreement with Knight as announced April 14, 2014. The options are set to expire on the fifth anniversary of the date of grant and were issued at an exercise price of $2.50 per share. The options are subject to the approval of the TSX Venture Exchange. MPH.VN: 2.370 (+0.010)
IIROC Trade Resumption - Medicure Inc.
Newsfile Corp - Thu Jun 11, 6:58AM CDT
Trading resumes in:
IIROC Trade Halt - Medicure Inc.
Newsfile Corp - Wed Jun 10, 2:42PM CDT
The following issues have been halted by IIROC:
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.16 (+0.33), BMRN: 141.67 (+1.54), TRGT: 2.68 (-0.06), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch), NVS: 103.22 (+3.20)
Global Tardive Dyskinesia Clinical Trials Report 2015
M2 - Fri May 22, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mndbr/tardive) has announced the addition of the "Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" report to their offering. Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tardive Dyskinesia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Neurocrine Biosciences, Inc. - Teva Pharmaceutical Industries Limited - UCB S.A. - Synchroneuron Inc. - Medicure Inc. Clinical Trial Overview of Top Institutes / Government - Beersheva Mental Health Center - Beijing Huilongguan Hospital - Taoyuan Mental Hospital - Baylor College of Medicine - Ben-Gurion University of the Negev - Centre for Addiction and Mental Health - Centre Hospitalier Universitaire, Amiens - Herzog Hospital - Lawson Health Research Institute - Parnassia Psycho Medical Centre For more information visit http://www.researchandmarkets.com/research/9mndbr/tardive
NBIX: 48.16 (+0.33), TEVA: 61.38 (-0.75)
Medicure Reports Financial Results for the First Quarter of 2015
CNW Group - Wed Apr 29, 6:11PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the first quarter ended March 31, 2015. MPH.VN: 2.370 (+0.010)
Medicure Q1 Results and Conference Call Dates
PR Newswire - Mon Apr 27, 12:32PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will release financial results for the first quarter after market close on Wednesday April 29, 2015. Medicure will hold a conference call regarding the results on Thursday April 30, 2015 at 8:00 am, Central Time. (9:00 am, Eastern Time). MPH.VN: 2.370 (+0.010)
Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT®
PR Newswire - Thu Apr 23, 10:14AM CDT
FDA Approves Labeling Supplement
MPH.VN: 2.370 (+0.010)
Medicure to present at the 2015 Bloom Burton & Co. Healthcare Conference
CNW Group - Wed Apr 22, 10:14AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the Company's President and Chief Operating Officer, Dawson Reimer, will present an overview of the Company at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 5, 2015 at 11:30 a.m. Eastern Time. MPH.VN: 2.370 (+0.010)
Medicure reports financial results for the seven months ended December 31, 2014
PR Newswire - Tue Apr 14, 10:35AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the seven months ended December 31, 2014. MPH.VN: 2.370 (+0.010)
Medicure announces grant of options
CNW Group - Fri Mar 27, 2:49PM CDT
Medicure Inc. (the "Company"
(TSXV:MPH, OTCQB:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 236,070 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 181,070 are set to expire on the tenth anniversary of the date of grant, 5,000 are set to expire on the third anniversary of the date of grant and 50,000 are set to expire on the first anniversary of the date of grant. All of the options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange. MPH.VN: 2.370 (+0.010)
Medicure announces issuance of shares under previously announced shares for debt settlement
PR Newswire - Fri Mar 20, 4:00PM CDT
Medicure Inc. (the "Company"
(TSXV:MPH, OTC:MCUJF.US) announces today that the Company has issued 108,206 of its common shares at a deemed price of $1.44 per common share extinguishing $155,816.64 of amounts owing to certain members of the Board of Directors and a consultant under shares for debt agreements originally entered into and announced on January 27, 2015. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation. MPH.VN: 2.370 (+0.010)
Medicure provides quarterly revenue on a calendar basis following change to year end
PR Newswire - Mon Feb 02, 9:00AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today provided detail on its historic calendar quarter revenue in anticipation of future reporting under the new financial reporting periods. This change in year end from May 31 to December 31 was previously announced on December 18, 2014. MPH.VN: 2.370 (+0.010)
